On September 17, 2026, Altis Labs announced that it closed a US$25-million Series A financing co-led by OrbiMed and Qiming Venture Partners USA, with participation from Innovation Endeavors, Benchstrength, Fusion Fund, the Cancer Breakthrough Fund, and others. Altis Labs intends to use the proceeds to expand its AI models across additional cancer types, scale commercial deployment with global biopharmaceutical partners, and advance AI endpoints as a new standard for oncology clinical trials.
Altis Labs is a Toronto-based AI endpoint company focused on accelerating oncology clinical development. Its flagship AI model, IPRO, generates survival predictions from routinely acquired radiology scans, enabling drug developers to detect and analyze treatment effects earlier and more reliably in clinical trials.
Osler, Hoskin & Harcourt LLP advised Altis Labs with a team consisting of Chad Bayne, Ryan Unruch, Jennifer Humphrey and Jordan Geist (Emerging and High Growth Companies).
Key Contact
Partner, Emerging and High Growth Companies, Toronto
Team
Partner, Emerging and High Growth Companies, Toronto
Associate, Emerging and High Growth Companies, Toronto
Associate, Emerging High Growth Companies, Toronto
